AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
MEDICAL
EU may limit sales of J&J's Eprex
The health care products giant fell 2% amid concerns French regulators won't let patients with chronic kidney failure keep using Johnson & Johnson's anemia drug, since Eprex has made anemia worse for some of the patients. J&J said it'll ask European regulators to change Eprex's label to address this issue. Amgen, which sells two rival anemia drugs, rose 3%.
Tenet revamps prices amid probe
The hospital chain scrapped a plan with Health Net that made the insurer pay more for patients with unusually high costs. The HMO will now pay a patient "per diem." That could portend a new pricing strategy -- which Tenet unveils Tuesday -- and maybe slower growth. Medicare is probing whether Tenet overbilled. Now HMOs are raising questions. Tenet fell 4%.
Quest to pay less for rival Unilab
The lab testing service firms will cut $60 mil from the price of Quest Diagnostics' buy of Unilab. The deal was worth some ...